(Stockholm, Sweden, October 12, 2021) In a renewed partnership Karolinska Institutet (KI) in Stockholm helps to validate ISAB’s new XposeALI® MP (Microperfusion) tool, including using it to test a Mars dust surrogate for European Space Agency as part of exploring future manned missions to Mars. XposeALI® MP is a highly automated new iteration of ISAB’s current cell culture module and is expected to do in vitro lung studies simpler, more consistent and more cost-effective – including for biologists, an important priority area for inhaled drug developers.
On Friday, October 8, ISAB renewed its long-standing partnership with KI by installing a PreciseInhale® aerosol generator and an upgraded XposeALI® system at KI’s facilities at Institute of Environmental Medicine (IMM) in Stockholm for a one-year loan. As part of the new agreement, KI will help validate XposeALI® MP with valuable R&D support. KI has a unique and in-depth experience of XposeALI®, after publishing several scientific articles about it and successfully exposing cells on its air-liquid interface (ALI) with aerosols from a variety of substances.
Tests inhaled “ Mars dust ”
The new partnership includes a project where KI will collaborate with the Human Space Exploration team within ESA (European Space Agency). KI intends to expose lung cells with a Mars dust surrogate, which will deliver important information for future manned expeditions to Mars.
Market potential for XposeALI® MP estimated at “ several million euros ”
XposeALI® MP (Microperfusion) is a new highly automated iteration of ISAB’s XposeALI® module, with an automated sampling phase, making the implementation of experiments easier and more cost-effective. XposeALI® MP is activated in vitro permeability studies for inhaled drugs to be more standardized and physiologically relevant. At present, research in inhaled drugs is against biological substances, ie. proteins rather than small molecules; permeability studies performed on XposeALI® MP can play an important role in understanding the pharmacokinetics of these larger molecules and how inhaled protein drugs will be absorbed and retained in the lungs.
The estimated market potential for XposeALI® MP of several million euros has been confirmed by several important users and companies in the market.
ISAB CEO Manoush Masarrat: “We really value our relationship with KI. Few groups have such deep knowledge of our systems. Being able to use that expertise to validate this new version of XposeALI® has great academic and commercial benefits for us and we look forward to starting this valuable collaboration with KI. “
For more information on inhalation sciences, please contact:
Manoush Masarrat, VD
Email: [email protected]
Mobile: +46 (0) 73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Science Sweden AB (publ) develops and commercializes world-leading inhalation research instruments and services. The company’s patented laboratory instruments PreciseInhale® and DissolvIt® enable researchers in the pharmaceutical industry to decide on drug pipeline at an early stage, saving time and resources for R&D departments and enabling researchers at academic institutions to define how aerosols and small particles affects our lungs, and so our health, when we inhale.
(c) 2021 Cision. All rights reserved., Source Press releases – English